MedPath

CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars

Phase 3
Completed
Conditions
Hypertrophic Scars
Keloids
Registration Number
NCT00993005
Lead Sponsor
Catalysis SL
Brief Summary

The purpose of the study is to assess the efficacy of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of Hypertrophic scars and keloids. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons to be recruited and randomized for the study is 90.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Hypertrophic wound or keloid with no treatment for more than 1 month.
  • Signed informed consent.
Exclusion Criteria
  • Usage of steroids within 30 days.
  • Malignant neoplastic conditions.
  • Alcoholism.
  • Handicap and/or psychiatric condition preventing treatment accomplishment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Length of the hypertrophic scar(s) and keloids measured by a millimetric ruler at week 12 (end of the treatment)12 weeks
Secondary Outcome Measures
NameTimeMethod
Occurrence of adverse effects at week 12 (end of the treatment)12 weeks
Photographs of lesions at week 12 (end of the treatment)12 weeks

Trial Locations

Locations (1)

"Cdte. Manuel Fajardo Rivero" Clinical-Surgical-Docent Hospital

🇨🇺

Havana City, Havana, Cuba

"Cdte. Manuel Fajardo Rivero" Clinical-Surgical-Docent Hospital
🇨🇺Havana City, Havana, Cuba

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.